Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046826 · ClinicalTrials.gov registry record · Phase 2
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
A Phase 2 study, sponsored by Nuvance Health.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00046826: Completed Phase 2 study, sponsored by Nuvance Health.
NCT00046826 is a Phase 2 study that has completed, run by Nuvance Health. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00046826, a Phase 2 study, has completed, sponsored by Nuvance Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with thalidomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and estramustine with thalidomide in treating patients who have prostate cancer previously treated with hormone therapy.
Interventions
- DRUG docetaxel
- DRUG thalidomide
- DRUG estramustine phosphate sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-09 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
What the finished NCT00046826 record still lists
NCT00046826 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which docetaxel is the first listed.
NCT00046826 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00046826 about?
NCT00046826 is a clinical study titled "Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy". RATIONALE: Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with thalidomide may kill more tumor cells. PURPOSE: Phase II trial ...
What is the current status of trial NCT00046826?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-09. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00046826?
The interventions under investigation include: docetaxel (DRUG), thalidomide (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00046826?
This trial is sponsored by Nuvance Health, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia